Two Australian researchers have made revolutionary
discoveries with the potential to offer exciting new approaches in the battle
against disease – one targeting tuberculosis and the other cancer – and are now
battling it out for top prize at the upcoming 2019 Centenary Institute Medical
The awards, which recognise and celebrate Australia’s
inspiring young researchers who are successfully challenging the big questions
of medical research, has a prize pool in excess of $50,000 on offer. The
finalists and their ground-breaking discoveries have now been officially announced.
Dr Elinor Hortle* (pictured left) from the Centenary Institute has been selected for her discovery that platelets (cells that help the body form clots to stop bleeding) have an active role in the development of tuberculosis (TB). The major implication of her work is that anti-platelet drugs including aspirin may be an effective therapy for tuberculosis. With TB disproportionately affecting the developing world, the ability to extend current treatment regimens with such a cheap, safe, clinically approved drug could have an enormous impact on the global control of this deadly infectious disease.
Dr Simone Park* (pictured right) from the Peter Doherty Institute for Infection & Immunity at The University of Melbourne is the other finalist. Her research is focused on better understanding how the immune system can be targeted and/or activated to treat disease including cancer. She discovered that specialised immune cells – known as tissue-resident memory T (TRM) cells – could suppress the growth of melanoma cancer cells without completely eliminating them. In identifying that TRM cells are critical players in the anti-cancer immune response, she believes that the targeting of these cells could open the door to a new and innovative strategy to improve cancer treatments.
The two finalists were chosen from 32 entries
submitted for the Centenary Institute Medical Innovation Awards, representing
22 research institutions and universities, across five Australian states.
“The selection of the two finalists was the
result of careful consideration from a line-up of distinguished judges
comprising some of the most prestigious scientists around the world,” said
Centenary Institute Executive Director Professor Mathew Vadas.
“It is enormously exciting to see the quality
of the applications for this award improve each year. Our future, as a high
performing and innovative nation in medical research, is firmly linked to the
long-term support of these wonderful talents,” he said.
The winner of the top award, the ‘In Memory of Neil Lawrence Prize’ will
receive $30,000 from Commonwealth Private to support their research, as well as
a perpetual Nick Mount hand blown glass trophy.
The runner-up will receive the ‘Bayer Innovation Award’ and $15,000 to
continue to develop their research. One of these two award winners will also be
presented the ‘Harvard Club of Australia
Foundation Travel Prize’ worth $5,000 for the purpose of travelling to
Harvard University, Boston, Massachusetts, USA to explore opportunities for
Choice Award’, voted on by the general public and research community has
taken place and was won by Dr Elise McGlashan from the Turner Institute for
Brain and Mental Health – Monash University, for her work showing that simple
changes to light exposure could dramatically increase the number of patients
who benefit from first-line antidepressant medications.
All three award winning scientists will be
recognised at the 2019 Centenary Institute Medical Innovation Awards
announcement ceremony, taking place in Sydney on Wednesday 21st August, 2019.
About the CIMIA: The annual Centenary Institute Medical Innovation Awards are designed to recognise and celebrate Australia’s bold young researchers who are taking risks and challenging the big questions of medical research, while promoting a domestic culture of brilliance in medical research. The finalists are selected and ranked after careful consideration by an international panel of adjudicators.
Presented in alphabetic order by surname
Read the full media release here.